237 related articles for article (PubMed ID: 23242435)
1. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
[TBL] [Abstract][Full Text] [Related]
2. Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
Christoph DC; Reyna-Asuncion B; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Gauler TC; Wohlschlaeger J; Schuler M; Eberhardt WE; Hirsch FR
Clin Lung Cancer; 2014 Sep; 15(5):320-30.e1-3. PubMed ID: 24993594
[TBL] [Abstract][Full Text] [Related]
3. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
7. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
[TBL] [Abstract][Full Text] [Related]
8. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.
Liu Y; Yin TJ; Zhou R; Zhou S; Fan L; Zhang RG
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1125-32. PubMed ID: 24067998
[TBL] [Abstract][Full Text] [Related]
9. Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.
Fennell DA; Myrand SP; Nguyen TS; Ferry D; Kerr KM; Maxwell P; Moore SD; Visseren-Grul C; Das M; Nicolson MC
PLoS One; 2014; 9(9):e107455. PubMed ID: 25250715
[TBL] [Abstract][Full Text] [Related]
10. Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).
Alvarez-Fernandez C; Perez-Arnillas Q; Ruiz-Echeverria L; Rodriguez-Rubi D; Sanchez-Lorenzo L; Li-Torres W; Izquierdo-Manuel M; Berros JP; Luque-Cabal M; Jimenez-Fonseca P; Villanueva-Palicio N; Esteban-Gonzalez E
Invest New Drugs; 2014 Apr; 32(2):377-81. PubMed ID: 23912258
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
13. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
14. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Yang M; Fan WF; Pu XL; Meng LJ; Wang J
J Chemother; 2017 Apr; 29(2):106-112. PubMed ID: 27866454
[TBL] [Abstract][Full Text] [Related]
15. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Hashemi Sadraei N; Feng Y; Du L; Fu P; Haque S; Dowlati A; Gollamudi J; Pennell NA; Mekhail T; Avril S; Farver C; Gerson SL; Sharma N
Lung Cancer; 2018 Dec; 126():48-54. PubMed ID: 30527192
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
Sun JM; Ahn JS; Jung SH; Sun J; Ha SY; Han J; Park K; Ahn MJ
J Clin Oncol; 2015 Aug; 33(22):2450-6. PubMed ID: 26124486
[TBL] [Abstract][Full Text] [Related]
17. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
He YW; Zhao ML; Yang XY; Zeng J; Deng QH; He JX
Cancer Chemother Pharmacol; 2015 Apr; 75(4):861-7. PubMed ID: 25732635
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Shaw AT; Varghese AM; Solomon BJ; Costa DB; Novello S; Mino-Kenudson M; Awad MM; Engelman JA; Riely GJ; Monica V; Yeap BY; Scagliotti GV
Ann Oncol; 2013 Jan; 24(1):59-66. PubMed ID: 22887466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
